T. Rowe Price Investment Management, Inc. Tango Therapeutics, Inc. Call Options Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|---|---|---|---|---|
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding TNGX
# of Institutions
123Shares Held
97.5MCall Options Held
1.1KPut Options Held
0-
Trv Gp Iv, LLC Boston, MA16.9MShares$40.1 Million88.92% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA10.7MShares$25.6 Million3.54% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA10.6MShares$25.3 Million1.14% of portfolio
-
Nextech Invest, Ltd. Zurich, V85.53MShares$13.2 Million1.76% of portfolio
-
Nextech Invest Ag5.53MShares$13.2 Million3.19% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $210M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...